01—Abstract
Summary
Summary of the 8-K filed October 17, 2025. Cited figures are marked; the original filing is the authoritative source.
Revolution Medicines, Inc. filed a Form 8-K dated October 16, 2025 to report an event under Item 8.01 (Other Events).
On October 16, 2025, the Company announced that the U.S. Food and Drug Administration has granted it a non-transferrable voucher for daraxonrasib, its RAS(ON) multi-selective inhibitor, under the Commissioner's National Priority Voucher pilot program. The filing is brief and does not disclose financial results, trial data, or any quantified financial terms associated with the voucher. Its substance is the regulatory designation itself: the voucher is tied to daraxonrasib and is stated to be non-transferrable, meaning it cannot be sold or assigned to another company under the terms described.
For investors, the key takeaway is that daraxonrasib has received a national priority voucher from the FDA. The filing itself does not state the specific benefits, timelines, or conditions attached to the voucher, so any assessment of its commercial or clinical impact must await further company disclosures.
02—Key points
Key Highlights
- On October 16, 2025, Revolution Medicines announced that the FDA granted it a non-transferrable voucher for daraxonrasib.
- Daraxonrasib is described in the filing as the Company's RAS(ON) multi-selective inhibitor.
- The voucher was granted under the Commissioner's National Priority Voucher pilot program.
- The voucher is non-transferrable, so it cannot be sold or assigned to another company.
- The filing is a brief Item 8.01 (Other Events) report and includes no financial statements or quantified financial terms.
- The filing does not state the specific benefits, timelines, or conditions attached to the voucher.
03—Questions
Frequently Asked Questions
What did Revolution Medicines announce in this filing?
The Company announced that the U.S. Food and Drug Administration has granted it a non-transferrable voucher for daraxonrasib, its RAS(ON) multi-selective inhibitor, under the Commissioner's National Priority Voucher pilot program.
What is the Commissioner's National Priority Voucher pilot program referenced in the filing?
The filing identifies the voucher as granted under the Commissioner's National Priority Voucher pilot program but does not describe the program's terms or the benefits it confers.
Can the voucher be transferred to another company?
No. The filing states that the voucher is non-transferrable.
What is daraxonrasib?
The filing describes daraxonrasib as the Company's RAS(ON) multi-selective inhibitor. The filing does not provide further details on its indication, development stage, or clinical data.
Does this filing include financial results or a financial impact?
No. The filing is a short Item 8.01 report about the FDA voucher and does not include financial results, financial statements, or any quantified financial impact.
04—Continue